Safety Study of SGN-CD70A in Cancer Patients

Status Completed

Clinical Trial Summary

This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02216890
Study type	Interventional
Source	Seattle Genetics, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	August 2014
Completion date	February 15, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04987203` - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma	Phase 3
Recruiting	`NCT06391879` - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated	`NCT03655613` - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC	Phase 1/Phase 2
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT05418387` - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona	N/A
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Completed	`NCT02853344` - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)	Phase 2
Terminated	`NCT04088500` - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma	Phase 2
Completed	`NCT05070637` - Circulating Tumor Cell Reducing No-touch Nephrectomy	N/A
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Not yet recruiting	`NCT06049030` - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Completed	`NCT01358721` - Phase I Biomarker Study (BMS-936558)	Phase 1
Active, not recruiting	`NCT04503148` - Anesthesia and Cancer Study: Renal Cell Carcinoma	N/A
Completed	`NCT02386826` - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme	Phase 1
Not yet recruiting	`NCT05808608` - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma	Phase 1/Phase 2
Withdrawn	`NCT03323710` - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma	Phase 2
Completed	`NCT03052504` - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy